Although the procedure is available globally within supportive jurisdictions, the long-term goal of Legaconetics is to leverage the existing patient network, and international banks to aggregate an IMSC-Exosome specific haplobank, for the purposes of creating a series of cell-lines for therapeutic purposes. This will allow mass-scaling of cost-effective, IP protected therapeutic applications, for highly targeted allogenic treatments, with a tremendously high safety profile, and proven efficacy.
The use of machine learning, LLM and AI in the data-processing, and leveraging the knowledge of world-leading scientists will place Legacinetics at the leading edge of IMSC-Exosome technology, on both autologous and allogenic pathways.
Haplobanking of induced mesenchymal stem cells (iMSCs) refers to the establishment of repositories of iMSCs derived from induced pluripotent stem cells (iPSCs), where the iPSCs are selected or engineered to have specific human leukocyte antigen (HLA) haplotypes.
These banks aim to provide off-the-shelf, allogeneic iMSC products that are immunologically compatible with a broad population, minimizing immune rejection in cell therapies Haplobanking of iMSCs is a transformative approach to delivering scalable, immunocompatible, and standardized cell therapies. By leveraging HLA-homozygous iPSCs, haplobanks enable off-the-shelf iMSCs for regenerative medicine, immunomodulation, and research, with benefits like broad compatibility, cost-effectiveness, and rejuvenated phenotypes.
Current efforts, including trials for GvHD and osteoarthritis, and advancements in gene editing and automation, are driving clinical translation. Challenges like population diversity and regulatory hurdles persist but are being addressed through global collaboration and innovation. As haplobanking matures, it could revolutionize allogeneic cell therapy, making iMSCs accessible to millions.
Legacinetics aims to take this process a further step, by creating an IMSC exosome-specific haplobank, and generating patentable cell-lines across a range of ailment.
Supports regenerative medicine, disease modeling, and drug discovery
Incorporates advancements in extracellular vesicles and exosomes for enhanced therapeutic applications
Utilises iMSC exosomes to improve safety profiles and drive advancements
Enables the production of scalable, standardised & rejuvenated mesenchymal stem cells
Whether you're interested in our services, seeking partnerships, or simply want to learn more about what we do, our team is here to assist! Contact us to discuss how you can benefit from partnering with Legacinetics.
